Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 106

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 106
---
roblasts (CAFs) and vascular permeability, which could support enhanced delivery and retention of therapeutic agents within the tumor
(EPR effect). However, these observations are based solely on preclinical findings. There can be no assurance that such effects will
be observed in human studies, that they will translate into clinically meaningful outcomes, or that regulators will view these results
as sufficient for approval.

<div align='center'>68</div>

Epidemiology and Market Size Estimates for Nano-Candesartan (Liposomal ARB) in Pancreatic Cancer

Global Revenue Potential for Nano-Candesartan in Pancreatic Cancer

U.S. incidence of Pancreatic Cancer is estimated
at ~61,000 new cases per year. [4] Global incidence is estimated at ~495,000 cases annually. [5]

Revenue assumptions (U.S. Market Only):

| - | Per Patient Per Month                                
 (PPPM) cost of treatment: estimated at $3,700–$7,400 |

| - | Assumed average duration of treatment           
 course (based on 3–4 months of use): 3.5 months |

| - | Per-patient course cost: $12,950 downside                                                       
 case scenario – $25,900 upside case scenario. Downside case scenario here reflects              
 pricing at the lower end of the estimated range, driven by reimbursement pressure, competition, 
 or a shorter treatment course. Upside case scenario reflects pricing at the upper end of        
 the estimated range, aligned with premium pricing observed for other liposomal oncology agents  
 demonstrating significant clinical benefit, or a longer treatment course. Final treatment       
 duration will depend on outcomes from future clinical trials.                                   |

U.S. TAM based on the estimated 61,000 patients/year may then translate
to:

~$790 million to $1.58 billion/year downside and upside case scenario
respectively.

Global Revenue Potential for Nano-Candesartan in Pancreatic Cancer

Global TAM assumed at roughly 4 times the size of the U.S. market
at around $690 million:

| - | ~$3.2 billion in downside case scenario |

| - | ~$6.3 billion in upside case scenario |

Serviceable Obtainable Market (SOM) for Nano-Candesartan in Pancreatic Cancer

At an assumed ~50% market penetration, projected
U.S. revenue could reach approximately $390–790 million annually under the downside and upside case scenarios. This reflects the